Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A 29-year-old man had a successful hair transplant at Dr. Ulusan Clinic in Izmir, Turkey, receiving over 4600 grafts and exosome injections. He started using finasteride and minoxidil daily a month after shaving his head, which improved his confidence and outlook on life.

The conversation is about seeking recommendations for clinics in Los Angeles that offer dutasteride mesotherapy for hair loss treatment. The user is asking for experiences and suggestions from the community.

A male in his early 40s, who experienced side effects from finasteride, used 2.5% topical spironolactone for one year with no side effects but minimal regrowth. He plans to try a 5% spironolactone solution next.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

The conversation discusses using scalp antiandrogens like RU58841, pyrilutamide, or fluridil on the face to reduce sebum production, noting that clascoterone (winlevi) is an approved facial antiandrogen with underwhelming reviews.

The conversation humorously discusses hair loss treatments, mentioning spironolactone and cyproterone acetate. It reflects a sense of frustration and satire about the effectiveness of these treatments.

The conversation is about trying dutasteride mesotherapy for hair loss, with concerns about its effectiveness and potential side effects compared to finasteride. The user is considering this treatment available in California.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

Dutasteride mesotherapy showed increased hair density and diameter without reducing serum DHT levels in a small study. However, the sample size was too small to make definitive claims about its efficacy.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.

The user is experiencing chest sensitivity and muscle ache after using topical finasteride for a month and is concerned about potential gynecomastia. They are considering asking their doctor for blood work to check estrogen levels and are questioning whether to stop using finasteride.

A 23-year-old is considering finasteride for hair loss but is concerned about worsening pre-existing mild gynecomastia. They plan to start with a low dose and monitor symptoms, seeking advice from others with similar experiences.

Spironolactone and finasteride are not recommended for women planning pregnancy due to birth defect risks. Both need to be stopped months before conception, and finasteride is generally not advised for women.

A 15-year-old is experiencing uneven hair loss, with one temple receding significantly. They are considering using finasteride, minoxidil, or dutasteride to slow hair loss before visiting a dermatologist, and may consider a hair transplant in the future.